Parkinson's disease biomarkers based on α-synuclein.
Biomarkers
Blotting, Western
Body Fluids
/ chemistry
Brain
/ diagnostic imaging
Cross-Sectional Studies
Disease Progression
Early Diagnosis
Enzyme-Linked Immunosorbent Assay
Gonads
/ chemistry
Humans
Longitudinal Studies
Mass Spectrometry
Mucous Membrane
/ chemistry
Organ Specificity
Parkinson Disease
/ diagnosis
Phosphorylation
Positron-Emission Tomography
Protein Aggregates
Protein Processing, Post-Translational
Salivary Glands
/ chemistry
Skin
/ chemistry
alpha-Synuclein
/ analysis
Parkinson's disease
biomarkers
α-synuclein
Journal
Journal of neurochemistry
ISSN: 1471-4159
Titre abrégé: J Neurochem
Pays: England
ID NLM: 2985190R
Informations de publication
Date de publication:
09 2019
09 2019
Historique:
received:
18
03
2019
revised:
05
05
2019
revised:
26
06
2019
accepted:
26
06
2019
pubmed:
3
7
2019
medline:
24
3
2020
entrez:
3
7
2019
Statut:
ppublish
Résumé
Parkinson's disease is the second most common neurodegenerative disorder after Alzheimer's disease and is estimated to affect approximately 1-4% of individuals aged over 60 years old. Although considerable efforts have been invested into developing disease-modifying therapies for Parkinson's disease, such efforts have been confounded by the difficulty in accurately diagnosing Parkinson's disease during life to enable accurate patient stratification for clinical trialling of candidate therapeutics. Therefore, the search for effective biomarkers that can be accurately evaluated during life with non-invasive means is a pressing issue in the field. Since the discovery of α-synuclein (α-syn) as a protein linked to a familial form of Parkinson's disease, later identified as the major protein component of the neuropathological hallmark of idiopathic Parkinson's disease, considerable interest has focused on this protein and its distinct conformers. We describe here the progress that has been made in the area of Parkinson's disease biomarker discovery with a focus on α-synuclein. In particular, we highlight the novel assays that have been employed and the increasing complexity in evaluating α-synuclein with regard to the considerable diversity of conformers that exist in the biofluids and peripheral tissues under disease conditions. "This article is part of the Special Issue Synuclein."
Substances chimiques
Biomarkers
0
Protein Aggregates
0
alpha-Synuclein
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
626-636Subventions
Organisme : Medical Research Council
ID : G1100540
Pays : United Kingdom
Informations de copyright
© 2019 International Society for Neurochemistry.
Références
Aasly J. O., Johansen K. K., Bronstad G., et al. (2014) Elevated levels of cerebrospinal fluid alpha-synuclein oligomers in healthy asymptomatic LRRK2 mutation carriers. Front. Aging Neurosci. 6, 248.
Antunes L., Frasquilho S., Ostaszewski M., et al. (2016) Similar alpha-Synuclein staining in the colon mucosa in patients with Parkinson's disease and controls. Mov. Disord. 31, 1567-1570.
Beach T. G., White C. L., 3rd, Hladik C. L., et al. (2009) Olfactory bulb alpha-synucleinopathy has high specificity and sensitivity for Lewy body disorders. Acta Neuropathol. 117, 169-174.
Beach T. G., Adler C. H., Dugger B. N., et al. (2013) Submandibular gland biopsy for the diagnosis of Parkinson disease. J. Neuropathol. Exp. Neurol. 72, 130-136.
Borghi R., Marchese R., Negro A., Marinelli L., Forloni G., Zaccheo D., Abbruzzese G. and Tabaton M. (2000) Full length α-synuclein is present in cerebrospinal fluid from Parkinson's disease and normal subjects. Neurosci. Lett. 287, 65-67.
Braak H., Del Tredici K., Rub U., de Vos R. A., Jansen Steur E. N. and Braak E. (2003) Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging 24, 197-211.
Carletti R., Campo F., Fusconi M., Pellicano C., De Vincentiis M., Pontieri F. E. and Di Gioia C. R. (2017) Phosphorylated alpha-synuclein immunoreactivity in nerve fibers from minor salivary glands in Parkinson's disease. Parkinsonism Relat. Disord. 38, 99-101.
Cersosimo M. G., Tumilasci O. R., Raina G. B., Benarroch E. E., Cardoso E. M., Micheli F. and Pazo J. H. (2009) Hyposialorrhea as an early manifestation of Parkinson disease. Auton. Neurosci. 150, 150-151.
Cersosimo M. G., Perandones C., Micheli F. E., Raina G. B., Beron A. M., Nasswetter G., Radrizzani M. and Benarroch E. E. (2011) Alpha-synuclein immunoreactivity in minor salivary gland biopsies of Parkinson's disease patients. Mov. Disord. 26, 188-190.
Chartier-Harlin M. C., Kachergus J., Roumier C., et al. (2004) Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet 364, 1167-1169.
Chung S. J., Kim J., Lee H. J., et al. (2016) Alpha-synuclein in gastric and colonic mucosa in Parkinson's disease: limited role as a biomarker. Mov. Disord. 31, 241-249.
Devic I., Hwang H., Edgar J. S., et al. (2011) Salivary α-synuclein and DJ-1: potential biomarkers for Parkinson's disease. Brain 134, e178-e178.
Donadio V., Incensi A., Leta V., et al. (2014) Skin nerve alpha-synuclein deposits: a biomarker for idiopathic Parkinson disease. Neurology 82, 1362-1369.
Donadio V., Incensi A., El-Agnaf O., et al. (2018) Skin alpha-synuclein deposits differ in clinical variants of synucleinopathy: an in vivo study. Sci. Rep. 8, 14246.
Doppler K., Ebert S., Uceyler N., Trenkwalder C., Ebentheuer J., Volkmann J. and Sommer C. (2014) Cutaneous neuropathy in Parkinson's disease: a window into brain pathology. Acta Neuropathol. 128, 99-109.
Duran R., Barrero F. J., Morales B., Luna J. D., Ramirez M. and Vives F. (2010) Plasma α-synuclein in patients with Parkinson's disease with and without treatment. Mov. Disord. 25, 489-493.
El-Agnaf O. M., Salem S. A., Paleologou K. E., Curran M. D., Gibson M. J., Court J. A., Schlossmacher M. G. and Allsop D. (2006) Detection of oligomeric forms of α-synuclein protein in human plasma as a potential biomarker for Parkinson’s disease. FASEB J. 20, 419-425.
Eusebi P., Giannandrea D., Biscetti L., Abraha I., Chiasserini D., Orso M., Calabresi P. and Parnetti L. (2017) Diagnostic utility of cerebrospinal fluid α-synuclein in Parkinson's disease: a systematic review and meta-analysis. Mov. Disord. 32, 1389-1400.
Fairfoul G., McGuire L. I., Pal S., et al. (2016) Alpha-synuclein RT-Qu IC in the CSF of patients with alpha-synucleinopathies. Ann. Clin. Transl. Neurol. 3, 812-818.
Foulds P. G., Mitchell J. D., Parker A., Turner R., Green G., Diggle P., Hasegawa M., Taylor M., Mann D. and Allsop D. (2011) Phosphorylated α-synuclein can be detected in blood plasma and is potentially a useful biomarker for Parkinson's disease. FASEB J. 25, 4127-4137.
Foulds P. G., Diggle P., Mitchell J. D., Parker A., Hasegawa M., Masuda-Suzukake M., Mann D. M. and Allsop D. (2013) A longitudinal study on α-synuclein in blood plasma as a biomarker for Parkinson's disease. Sci. Rep. 3, 2540.
Gao L., Tang H., Nie K., et al. (2015) Cerebrospinal fluid alpha-synuclein as a biomarker for Parkinson's disease diagnosis: a systematic review and meta-analysis. Int. J. Neurosci. 125, 645-654.
Garrido A., AldecoaI., Gelpi E., Tolosa E.. (2017) Aggregation of alpha-synuclein in the gonadal tissue of 2 patients with Parkinson disease. JAMA Neurol. 74, 606-607.
Gelb D. J., Oliver E. and Gilman S. (1999) Diagnostic criteria for Parkinson disease. Arch. Neurol. 56, 33-39.
Gerendai I., Banczerowski P. and Halász B. (2005) Functional significance of the innervation of the gonads. Endocrine 28, 309-18.
Gibbons C. H., Wang N. and Freeman R. (2017) Cutaneous alpha-synuclein from paraffin embedded autopsy specimens in Parkinson's disease. J. Parkinsons Dis. 7, 503-509.
Goldman J. G., Andrews H., Amara A., et al. (2018) Cerebrospinal fluid, plasma, and saliva in the BioFIND study: relationships among biomarkers and Parkinson's disease features. Mov. Disord. 33, 282-288.
Groveman B. R., Orrù C. D., Hughson A. G., Raymond L. D., Zanusso G., Ghetti B., Campbell K. J., Safar J., Galasko D. and Caughey B. (2018) Rapid and ultra-sensitive quantitation of disease-associated α-synuclein seeds in brain and cerebrospinal fluid by αSyn RT-QuIC. Acta Neuropathol. Commun. 6, 7.
Hanagasi H. A., Tufekcioglu Z. and Emre M. (2017) Dementia in Parkinson's disease. J. Neurol. Sci. 374, 26-31.
Hansson O., Hall S., Öhrfelt A., et al. (2014) Levels of cerebrospinal fluid α-synuclein oligomers are increased in Parkinson’s disease with dementia and dementia with Lewy bodies compared to Alzheimer’s disease. Alzheimers Res. Ther. 6, 25.
Hong Z., Shi M., Chung K. A., et al. (2010) DJ-1 and α-synuclein in human cerebrospinal fluid as biomarkers of Parkinson’s disease. Brain 133, 713-726.
Jakowec M. W., Petzinger G. M., Sastry S., Donaldson D. M., McCormack A. and Langston J. W. (1998) The native form of α-synuclein is not found in the cerebrospinal fluid of patients with Parkinson's disease or normal controls. Neurosci. Lett. 253, 13-16.
Kang J. H., Irwin D. J., Chen-Plotkin A. S., et al. (2013) Association of cerebrospinal fluid beta-amyloid 1-42, T-tau, P-tau181, and alpha-synuclein levels with clinical features of drug-naive patients with early Parkinson disease. JAMA Neurol. 70, 1277-1287.
Kang W., Chen W., Yang Q., et al. (2016) Salivary total α-synuclein, oligomeric α-synuclein and SNCA variants in Parkinson’s disease patients. Sci. Rep. 6, 1.
Kang U. J., Boehme A. K., Fairfoul G., Shahnawaz M., Ma T. C., Hutten S. J., Green A. and Soto C. (2019) Comparative study of cerebrospinal fluid α-synuclein seeding aggregation assays for diagnosis of Parkinson's disease. Mov. Disord. 34, 536-544.
Kirik D., Rosenblad C., Burger C., Lundberg C., Johansen T. E., Muzyczka N., Mandel R. J. and Bjorklund A. (2002) Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal system. J. Neurosci. 22, 2780-2791.
Lebouvier T., Neunlist M., Bruley des Varannes S., et al. (2010) Colonic biopsies to assess the neuropathology of Parkinson's disease and its relationship with symptoms. PLoS ONE 5, e12728.
Lee P. H., Lee G., Park H. J., Bang O. Y., Joo I. S. and Huh K. (2006) The plasma alpha-synuclein levels in patients with Parkinson’s disease and multiple system atrophy. J. Neural. Transm. 113, 1435-1439.
Lesage S., Anheim M., Letournel F., et al. (2013) G51D alpha-synuclein mutation causes a novel parkinsonian-pyramidal syndrome. Ann. Neurol. 73, 459-471.
Li Q. X., San Mok S., Laughton K. M., McLean C. A., Cappai R., Masters C. L., Culvenor J. G. and Horne M. K. (2007) Plasma α-synuclein is decreased in subjects with Parkinson's disease. Exp. Neurol. 204, 583-588.
Lin C. H., Yang S. Y., Horng H. E., Yang C. C., Chieh J. J., Chen H. H., Liu B.-H. and Chiu M. J. (2017) Plasma α-synuclein predicts cognitive decline in Parkinson's disease. J. Neurol. Neurosurg. Psychiatry. 88, 818-824.
Luk K. C., Song C., O'Brien P., Stieber A., Branch J. R., Brunden K. R., Trojanowski J. Q. and Lee V. M. (2009) Exogenous alpha-synuclein fibrils seed the formation of Lewy body-like intracellular inclusions in cultured cells. Proc. Natl Acad. Sci. USA 106, 20051-20056.
Maass F., Schulz I., Lingor P., Mollenhauer B. and Bähr M. (2018) Cerebrospinal fluid biomarker for Parkinson's disease: an overview. Mol. Cell. Neurosci. 97, 60-66..
Majbour N. K., Vaikath N. N., Eusebi P., et al. (2016) Longitudinal changes in CSF alpha-synuclein species reflect Parkinson's disease progression. Mov. Disord. 31, 1535-1542.
Mano Y., Nakamuro T., Takayanagi T. and Mayer R. F. (1994) Sweat function in Parkinson's disease. J. Neurol. 241, 573-576.
Marsili L., Rizzo G. and Colosimo C. (2018) Diagnostic criteria for Parkinson's disease: from James Parkinson to the concept of prodromal disease. Front. Neurol. 9, 156.
Masliah E., Rockenstein E., Veinbergs I., Mallory M., Hashimoto M., Takeda A., Sagara Y., Sisk A. and Mucke L. (2000) Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. Science 287, 1265-1269.
Mata I. F., Shi M., Agarwal P., et al. (2010) SNCA variant associated with Parkinson disease and plasma α-synuclein level. Arch. Neurol. 67, 1350-1356.
Michell A. W., Luheshi L. M. and Barker R. A. (2005) Skin and platelet alpha-synuclein as peripheral biomarkers of Parkinson's disease. Neurosci. Lett. 381, 294-298.
Mollenhauer B., Locascio J. J., Schulz-Schaeffer W., Sixel-Döring F., Trenkwalder C. and Schlossmacher M. G. (2011) α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study. Lancet Neurol. 10, 230-240.
Mollenhauer B., Trautmann E., Taylor P., Manninger P., Sixel-Döring F., Ebentheuer J., Trenkwalder C. and Schlossmacher M. G. (2013) Total CSF α-synuclein is lower in de novo Parkinson patients than in healthy subjects. Neurosci. Lett. 532, 44-48.
Mollenhauer B., Bowman F. D., Drake D., et al. (2018) Antibody-based methods for the measurement of α-synuclein concentration in human cerebrospinal fluid-method comparison and round robin study. J. Neurochem. 149, 126-138.
Murphy K. E., Karaconji T., Hardman C. D. and Halliday G. M. (2008) Excessive dopamine neuron loss in progressive supranuclear palsy. Mov. Disord. 23, 607-610.
O'Sullivan S. S., Massey L. A., Williams D. R., Silveira-Moriyama L., Kempster P. A., Holton J. l., Revesz T. and Lees A. J. (2008) Clinical outcomes of progressive supranuclear palsy and multiple system atrophy. Brain 131, 1362-1372.
Paleologou K. E., Kragh C. L., Mann D. M., Salem S. A., Al-Shami R., Allsop D., Hassan A. H., Jensen P. H. and El-Agnaf O. M. (2009) Detection of elevated levels of soluble alpha-synuclein oligomers in post-mortem brain extracts from patients with dementia with Lewy bodies. Brain 132, 1093-1101.
Papagiannakis N., Koros C., Stamelou M., et al. (2018) Alpha-synuclein levels and dimerization in erythrocytes of Parkinson’s disease patients. 20th International congress of International Parkinson and Movement Disorder Society.
Park M. J., Cheon S. M., Bae H. R., Kim S. H. and Kim J. W. (2011) Elevated levels of α-synuclein oligomer in the cerebrospinal fluid of drug-naïve patients with Parkinson's disease. J. Clin. Neurol. 7, 215-222.
Parkinson J. (2002) An essay on the shaking palsy. The Journal of neuropsychiatry and clinical neurosciences 14, 223-236.
Parnetti L., Chiasserini D., Bellomo G., et al. (2011) Cerebrospinal fluid Tau/α-synuclein ratio in Parkinson's disease and degenerative dementias. Mov. Disord. 26, 1428-1435.
Parnetti L., Chiasserini D., Persichetti E., et al. (2014a) Cerebrospinal fluid lysosomal enzymes and alpha-synuclein in Parkinson's disease. Mov. Disord. 29, 1019-1027.
Parnetti L., Farotti L., Eusebi P., et al. (2014b) Differential role of CSF alpha-synuclein species, tau, and Aβ42 in Parkinson's disease. Front. Aging Neurosci. 6, 53.
Polymeropoulos M. H., Lavedan C. and Leroy E. et al. (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276, 2045-2047.
Postuma R. B., Berg D., Stern M., et al. (2015) MDS clinical diagnostic criteria for Parkinson's disease. Mov. Disord. 30, 1591-1601.
Pouclet H., Lebouvier T., Coron E., Des Varannes S. B., Neunlist M. and Derkinderen P. (2012) A comparison between colonic submucosa and mucosa to detect Lewy pathology in Parkinson's disease. Neurogastroenterol. Motil. 24, e202-205.
Proukakis C., Dudzik C. G., Brier T., MacKay D. S., Cooper J. M., Millhauser G. L., Houlden H. and Schapira A. H. (2013) A novel alpha-synuclein missense mutation in Parkinson disease. Neurology 80, 1062-1064.
van der Putten H., Wiederhold K. H., Probst A., et al. (2000) Neuropathology in mice expressing human alpha-synuclein. J. Neurosci. 20, 6021-6029.
Rey N. L., Steiner J. A., Maroof N., Luk K. C., Madaj Z., Trojanowski J. Q., Lee V. M.-Y. and Brundin P. (2016) Widespread transneuronal propagation of α-synucleinopathy triggered in olfactory bulb mimics prodromal Parkinson’s disease. J. Exp. Med. 213, 1759-1778.
Rizzo G., Copetti M., Arcuti S., Martino D., Fontana A. and Logroscino G. (2016) Accuracy of clinical diagnosis of Parkinson disease: a systematic review and meta-analysis. Neurology 86, 566-576.
Rodriguez-Leyva I., Chi-Ahumada E., Mejia M., et al. (2017) The presence of alpha-synuclein in skin from melanoma and patients with Parkinson's disease. Mov. Disord. Clin. Pract. 4, 724-732.
Saito Y., Shioya A., Sano T., Sumikura H., Murata M. and Murayama S. (2016) Lewy body pathology involves the olfactory cells in Parkinson's disease and related disorders. Mov. Disord. 31, 135-138.
Satake W., Nakabayashi Y., Mizuta I., et al. (2009) Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease. Nat. Genet. 41, 1303-1307.
Schrag A., Horsfall L., Walters K., Noyce A. and Petersen I. (2015) Prediagnostic presentations of Parkinson's disease in primary care: a case-control study. Lancet Neurol. 14, 57-64.
Shah A., Hiew K. W., Han P., Parsons R. B., Chang R. C. C. and Legido-Quigley C. (2017) Alpha-synuclein in bio fluids and tissues as a potential biomarker for Parkinson’s disease. J. Alzheimers Parkinsonism Dement. 2.
Shahnawaz M., Tokuda T., Waragai M., Mendez N., Ishii R., Trenkwalder C., Mollenhauer B. and Soto C. (2017) Development of a biochemical diagnosis of Parkinson disease by detection of alpha-synuclein misfolded aggregates in cerebrospinal fluid. JAMA Neurol. 74, 163-172.
Shannon K. M., Keshavarzian A., Dodiya H. B., Jakate S. and Kordower J. H. (2012) Is alpha-synuclein in the colon a biomarker for premotor Parkinson's disease? Evidence from 3 cases. Mov. Disord. 27, 716-719.
Parkinson J. (2002) An essay on the shaking palsy. The Journal of neuropsychiatry and clinical neurosciences 14, 223-236.
Shi M., Zabetian C. P., Hancock A. M., et al. (2010) Significance and confounders of peripheral DJ-1 and alpha-synuclein in Parkinson's disease. Neurosci. Lett. 480, 78-82.
Simon-Sanchez J., Schulte C., Bras J. M., et al. (2009) Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat. Genet. 41, 1308-1312.
Singleton A. B., Farrer M., Johnson J., et al. (2003) alpha-Synuclein locus triplication causes Parkinson's disease. Science 302, 841.
Spillantini M. G., Schmidt M. L., Lee V. M., Trojanowski J. Q., Jakes R. and Goedert M. (1997) Alpha-synuclein in Lewy bodies. Nature 388, 839.
Spira P. J., Sharpe D. M., Halliday G., Cavanagh J. and Nicholson G. A. (2001) Clinical and pathological features of a Parkinsonian syndrome in a family with an Ala53Thr alpha-synuclein mutation. Ann. Neurol. 49, 313-319.
Stewart T., Liu C., Ginghina C., Cain K. C., Auinger P., Cholerton B., Shi M., Zhang J. and Parkinson Study Group DATATOP (2014) Cerebrospinal fluid alpha-synuclein predicts cognitive decline in Parkinson disease progression in the DATATOP cohort. Am. J. Pathol. 184, 966-975.
Stewart T., Sossi V., Aasly J. O., et al. (2015) Phosphorylated α-synuclein in Parkinson’s disease: correlation depends on disease severity. Acta Neuropathol. Commun. 3, 7.
Tokuda T., Salem S. A., Allsop D., Mizuno T., Nakagawa M., Qureshi M. M., Locascio J. J., Schlossmacher M. G. and El-Agnaf O. M. (2006) Decreased α-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson’s disease. Biochem. Biophys. Res. Comm. 349, 162-166.
Tokuda T., Qureshi M. M., Ardah M. T., Varghese S., Shehab S. A. S., Kasai T., Ishigami N., Tamaoka A., Nakagawa M. and El-Agnaf O. M. A. (2010) Detection of elevated levels of α-synuclein oligomers in CSF from patients with Parkinson disease. Neurology 75, 1766-1770.
Del Tredici K., Hawkes C. H., Ghebremedhin E. and Braak H. (2010) Lewy pathology in the submandibular gland of individuals with incidental Lewy body disease and sporadic Parkinson's disease. Acta Neuropathol. 119, 703-713.
Trojanowski J. Q. and Growdon J. H. (1998) A new consensus report on biomarkers for the early antemortem diagnosis of Alzheimer disease: current status, relevance to drug discovery, and recommendations for future research. J. Neuropathol. Exp. Neurol. 57, 643-644.
Villar-Piqué A., Lopes da Fonseca T. and Outeiro T. F. (2016) Structure, function and toxicity of alpha-synuclein: the Bermuda triangle in synucleinopathies. J. Neurochem. 139(Suppl 1), 240-255.
Vivacqua G., Latorre A., Suppa A., Nardi M., Pietracupa S., Mancinelli R., Fabbrini G., Colosimo C., Gaudio E. and Berardelli A. (2016) Abnormal salivary total and oligomeric alpha-synuclein in Parkinson’s disease. PLoS ONE 11, e0151-e0156.
Vivacqua G., Suppa A., Mancinelli R., Belvisi D., Fabbrini A., Costanzo M., Formica A., Onori P., Fabbrini G. and Berardelli A. (2019) Salivary alpha-synuclein in the diagnosis of Parkinson's disease and progressive supranuclear palsy. Parkinsonism Relat. Disord..
Wang Y., Shi M., Chung K. A., et al (2012) Phosphorylated α-synuclein in Parkinson’s disease. Sci. Transl. Med. 4, 121ra20-121ra20.
Wang X., Yu S., Li F. and Feng T. (2015) Detection of α-synuclein oligomers in red blood cells as a potential biomarker of Parkinson’s disease. Neurosci. Lett. 599, 115-119.
Watanabe H., Saito Y., Terao S., Ando T., Kachi T., Mukai E., Aiba I., Abe Y., Tamakoshi A., Doyu M. and Hirayama M. (2002) Progression and prognosis in multiple system atrophy: an analysis of 230 Japanese patients. Brain 125, 1070-1083.
Winner B., Jappelli R., Maji S. K., et al. (2011) In vivo demonstration that alpha-synuclein oligomers are toxic. Proc. Natl Acad. Sci. USA 108, 4194-4199.
Witt M., Bormann K., Gudziol V., Pehlke K., Barth K., Minovi A., Hahner A., Reichmann H. and Hummel T. (2009) Biopsies of olfactory epithelium in patients with Parkinson's disease. Mov. Disord. 24, 906-914.
Yanamandra K., Gruden M. A., Casaite V., Meskys R., Forsgren L. and Morozova-Roche L. A. (2011) α-Synuclein reactive antibodies as diagnostic biomarkers in blood sera of Parkinson's disease patients. PLoS ONE 6, e18513.
Zarranz J. J., Alegre J., Gomez-Esteban J. C., et al. (2004) The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann. Neurol. 55, 164-173.